– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –

– Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses –

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that new data from the Phase 3 INDIGO trial evaluating obexelimab in immunoglobulin G4-related disease (IgG4-RD) will be presented at two upcoming scientific meetings: the 6th International Symposium on IgG4-Related Disease, taking place October 8-10, in Cambridge, Massachusetts, and American College of Rheumatology (ACR) Convergence 2026, taking place November 6-11, 2026, in Orlando, Florida.

Longer-term flare protection and safety data from the INDIGO open-label extension will be presented on October 10 at the 6th International Symposium on IgG4-Related Disease. Additional presentations across both meetings include analyses evaluating glucocorticoid-associated toxicity and vaccine responses among patients with IgG4-RD treated with obexelimab.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.